Navigation Links
HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
Date:2/24/2011

n in cash and cash equivalents at December 31, 2009, and reflects incorporation of proceeds from the Company's common stock and convertible notes public offerings in 2010.

HeartWare will host a conference call on Thursday, February 24, 2011 at 8:00 a.m. U.S. Eastern Standard Time (being midnight Australian Eastern Daylight Time, between February 24 and February 25, 2011) to discuss the Company's financial results, highlights from the quarter and full year, and business outlook.  The call may be accessed by dialing 1-877-941-2322 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the United States, dial +1-480-629-9715.  Doug Godshall, President and Chief Executive Officer and David McIntyre, Chief Financial Officer and Chief Operating Officer, will host the conference call.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Fourth Quarter Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

About HeartWare InternationalHeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and des
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
2. HeartWare to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
4. HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
5. HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
6. HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock
7. HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
8. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
9. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
(Date:7/25/2014)... , July 25, 2014 Cardinal Health will ... pharmacies as winners of its prestigious Independent Pharmacy Best ... , one of the nation,s largest gatherings of independent ... – family-owned pharmacies from Ohio , ... – were selected for implementing exceptionally creative ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... 18, 2011 Amarin Corporation plc (Nasdaq: AMRN ... disease, today reported positive, statistically significant top-line results from its ... Phase 3 trial met its primary and secondary efficacy endpoints ... The purpose of the ANCHOR trial was ...
... a speech delivered Wednesday, President Obama outlined a framework ... the President discussed Medicare and his proposals to decrease ... proposals is to "speed generic brands of medicine onto ... to his continued call to reduce the length of ...
Cached Medicine Technology:Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8BIOCOM Response to Health Portion of President's Speech at George Washington University 2
(Date:7/27/2014)... analysis of hepatitis E virus (HEV) transmission by blood ... England have HEV in their plasma. The findings, published ... HEV-containing blood components (eg, red cells, platelets, and fresh ... in England. , The study retrospectively screened 225 ... between Oct, 2012 and Sept, 2013 for HEV RNA. ...
(Date:7/27/2014)... 2014 The report, “Glass Fiber ... By Raw Material, By Manufacturing Process, By Application ... By Geography – Global Trends & Forecast to ... market with an analysis and forecast by value ... and 107 figures spread through 347 slides and ...
(Date:7/27/2014)... medication to treat asthma and pneumonia can become ineffective. , ... drugs widely used to treat lung diseases work with the ... is caused by an infection, affects around 1 in 1000 ... children, the elderly, smokers and those with an underlying health ... UK are affected by asthma and the NHS spends around ...
(Date:7/27/2014)... Over the past five years, the ... well, thanks to many consumers valuing the taste and ... Coffee Association of Canada's Canadian Coffee Drinking Study in ... coffee per day. “This trend, coupled with many studies ... drinking tea on a daily basis, has stimulated consumer ...
(Date:7/27/2014)... 27, 2014 The report, “Oil Filter ... LCVs & HCVs), Market Type (OE & Aftermarket), Filter ... & Geography - Industry Trends & Forecast to 2018”, ... filters market with analysis and forecasting of the global ... is estimated to reach a revenue of $6.1 billion ...
Breaking Medicine News(10 mins):Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5
... U.S. households where English is not the primary language ... Medical Center researcher has found. , In a study ... Dr. Glenn Flores, professor of pediatrics at UT Southwestern ... of Children,s Health to examine whether disparities exist for ...
... BEDFORD, Mass., June 10 Insulet Corporation,(the "Company") (Nasdaq: ... a private,offering of $75 million in aggregate principal amount ... qualified institutional buyers in,reliance on Rule 144A under the ... the initial purchasers an option to purchase up to ...
... cardiac,arrest is a leading cause of death in ... it is imperative that every school develop an,emergency ... need to respond,effectively to children and adults who ... CPR and use an automated external defibrillator,(AED) are ...
... ,Best of Healthcare Furniture, ... Category for Third Straight ... by,Steelcase won the Gold Award in the Healthcare Furniture ... state-of-the-art product,design, technological innovation and environmental sustainability., (Photo: ...
... to kill cancer cells offer a promising strategy for ... body,s natural defenses often eliminate the viruses before they ... study by researchers at the Ohio State University Comprehensive ... improve this therapy for brain cancer patients. , The ...
... Snowe,(R-ME), member of the Senate Finance Committee, has ... pharmacy-related provisions to provide,prompt payment of Medicare Part ... Medicaid reimbursement cuts for generic prescription,drugs. In response, ... in,Camden, ME and a member of the National ...
Cached Medicine News:Health News:Children in non-English-speaking households face many health disparities, researcher concludes 2Health News:Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes 2Health News:Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes 3Health News:Statement of Robert O'Connor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act 2Health News:Three-peat: Nurture(R) Strikes Gold Again at NeoCon 2Health News:Cancer-killing viruses influence tumor blood-vessel growth 2Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2
... isotopic anemia assays feature ... ,pipetting steps for greater ... the processes ,involved in ... benefit to your laboratory ...
... Autoimmunity Screening Panel 1 is an ... and detection,of autoantibodies against various specific ... in serum, and is used,as an ... lupus erythematosus (SLE), mixed connective tissue ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... are compatible with multichannel pipettors, which allows ... pipetting steps required to prepare and place ... Ask Immuno Concepts for more information about ... formats are noted with an * after ...
Medicine Products: